These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Vascular manifestations in systemic sclerosis (scleroderma)]. Cafagna D; Melon F; Balbi M; Ponte E Minerva Med; 1998 May; 89(5):153-61. PubMed ID: 9676180 [TBL] [Abstract][Full Text] [Related]
23. Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. Denton CP; Xu S; Welsh KI; Pearson JD; Black CM J Rheumatol; 1996 Apr; 23(4):633-8. PubMed ID: 8730117 [TBL] [Abstract][Full Text] [Related]
24. Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis. Romano E; Manetti M; Rosa I; Fioretto BS; Ibba-Manneschi L; Matucci-Cerinic M; Guiducci S Ann Rheum Dis; 2018 Nov; 77(11):1665-1674. PubMed ID: 30021803 [TBL] [Abstract][Full Text] [Related]
25. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Yamamoto T Arch Dermatol Res; 2006 Feb; 297(8):333-44. PubMed ID: 16402183 [TBL] [Abstract][Full Text] [Related]
27. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis. Hua-Huy T; Dinh-Xuan AT Pathol Biol (Paris); 2015 Apr; 63(2):61-8. PubMed ID: 25818311 [TBL] [Abstract][Full Text] [Related]
28. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Manetti M; Rosa I; Milia AF; Guiducci S; Carmeliet P; Ibba-Manneschi L; Matucci-Cerinic M Ann Rheum Dis; 2014 Sep; 73(9):1700-9. PubMed ID: 23852693 [TBL] [Abstract][Full Text] [Related]
29. Molecular pathways as novel therapeutic targets in systemic sclerosis. Trojanowska M; Varga J Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537 [TBL] [Abstract][Full Text] [Related]
31. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders. Ogawa R; Akaishi S Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277 [TBL] [Abstract][Full Text] [Related]
32. Origin of fibrosing cells in systemic sclerosis. Ebmeier S; Horsley V Curr Opin Rheumatol; 2015 Nov; 27(6):555-62. PubMed ID: 26352735 [TBL] [Abstract][Full Text] [Related]
33. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Claman HN; Giorno RC; Seibold JR Arthritis Rheum; 1991 Dec; 34(12):1495-501. PubMed ID: 1720957 [TBL] [Abstract][Full Text] [Related]
34. Vascular damage and lack of angiogenesis in systemic sclerosis skin. Konttinen YT; Mackiewicz Z; Ruuttila P; Ceponis A; Sukura A; Povilenaite D; Hukkanen M; Virtanen I Clin Rheumatol; 2003 Sep; 22(3):196-202. PubMed ID: 14505210 [TBL] [Abstract][Full Text] [Related]